Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Hyperlipoproteinemias

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 24 articles: HTML format

Single Articles

April 2026
1. MARSTON NA, Bergmark BA, Sabatine MS
   Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. Reply.
   N Engl J Med. 2026;394:1763-1764.
   PubMed    
   
   
   
2. WANG S, Fan Z
   Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.
   N Engl J Med. 2026;394:1763.
   PubMed    
   
   
   
3. CHEN R, Lu S, Chen M
   Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.
   N Engl J Med. 2026;394:1762.
   PubMed    
   
   
   February 2026
4. NAVAR AM, Mikhailova E, Catapano AL, Banka P, et al
   A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
   N Engl J Med. 2026;394:529-539.
   PubMed     Abstract available
   
   
   
5. SCHUNKERT H, Natarajan P, Samani NJ
   The Inherited Basis of Coronary Artery Disease.
   N Engl J Med. 2026;394:576-587.
   PubMed     Abstract available
   
   
   January 2026
6. MORRIS PB
   CORE Principles in the Management of Severe Hypertriglyceridemia.
   N Engl J Med. 2026;394:509-510.
   PubMed    
   
   
   
7. BERGMARK BA, Marston NA, Sabatine MS
   Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. Reply.
   N Engl J Med. 2026;394:99.
   PubMed    
   
   
   
8. TOMLINSON B
   Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
   N Engl J Med. 2026;394:99.
   PubMed    
   
   
   
9. PERLEMUTER G, Voican C
   Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
   N Engl J Med. 2026;394:98-99.
   PubMed    
   
   
   November 2025
10. LAFFIN LJ, Nicholls SJ, Scott RS, Clifton PM, et al
    Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
    N Engl J Med. 2025;393:2119-2130.
    PubMed     Abstract available
    
    
    
11. MARSTON NA, Bergmark BA, Alexander VJ, Prohaska TA, et al
    Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512761.
    PubMed     Abstract available
    
    
    August 2025
12. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2507227.
    PubMed     Abstract available
    
    
    July 2025
13. MCFARLAND R, Hyslop LA, Feeney C, Pillai RN, et al
    Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.
    N Engl J Med. 2025;393:461-468.
    PubMed     Abstract available
    
    
    May 2025
14. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
    PubMed     Abstract available
    
    
    March 2025
15. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    September 2024
16. WATTS GF, Rosenson RS, Hegele RA, Goldberg IJ, et al
    Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
    N Engl J Med. 2024 Sep 2. doi: 10.1056/NEJMoa2409368.
    PubMed     Abstract available
    
    
    August 2024
17. FABBRINI E, Rady B, Koshkina A, Jeon JY, et al
    Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD.
    N Engl J Med. 2024;391:475-476.
    PubMed    
    
    
    May 2024
18. ROSENSON RS, Gaudet D, Hegele RA, Ballantyne CM, et al
    Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMoa2404147.
    PubMed     Abstract available
    
    
    
19. BALLANTYNE CM, Vasas S, Azizad M, Clifton P, et al
    Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
    N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143.
    PubMed     Abstract available
    
    
    April 2024
20. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    PubMed     Abstract available
    
    
    
21. WATTS GF
    Shooting the Messenger to Treat Hypertriglyceridemia.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMe2402653.
    PubMed    
    
    
    
22. STROES ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, et al
    Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2400201.
    PubMed     Abstract available
    
    
    February 2024
23. ALEXANDER VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, et al
    Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
    N Engl J Med. 2024;390:476-477.
    PubMed    
    
    
    April 2023
24. ALEXANDER JH
    Benefits of Bempedoic Acid - Clearer Now.
    N Engl J Med. 2023;388:1425-1426.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum